As of 4:02pm ET
| -5.28 / -12.90%|
Novo Nordisk AS engages in the research, development, manufacture, and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care; and Biopharmaceuticals segments. The Diabetes and Obesity Care segment covers insulins, glucagon-like-peptide 1, other protein-related products, oral anti-diabetic drugs and obesity. The Biopharmaceuticals segment handles the research, development, manufacture, and distribution of products within the areas of haemophilia, growth hormone, hormone replacement, inflammation and other therapy areas. The company was founded in 1923 by August Krogh, Marie Krogh, Hans Christian Hagedorn, August Kongsted, Harald Pedersen, and Thorvald Pedersen and is headquartered in Bagsværd, Denmark.
|Lars Rebien Sørensen||President & Chief Executive Officer|
|Jesper Brandgaard||Chief Financial Officer & Executive Vice President|
|Mads Krogsgaard Thomsen||Chief Science Officer & Executive Vice President|
|Alan C. Moses||Global Chief Medical Officer|
|Mads Krogsgaard||Chief Science Officer|